
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals has demonstrated a positive outlook primarily through the successful expansion of its Cortrophin sales force in early 2025, which has significantly contributed to the product's success. The company’s data-driven approach, supported by its weekly TRx tracker, indicates that Cortrophin is poised to outperform previous revenue expectations, consequently leading to potential revenue estimate increases and multiple expansions. Furthermore, ANI's enhanced capability to address payer-related inquiries and secure script approvals positions the company favorably for ongoing financial growth.
Bears say
ANI Pharmaceuticals Inc. faces multiple significant risks that contribute to a negative outlook on its stock, including a considerable debt load exceeding $600 million, which may limit financial flexibility and operational investments. Additionally, the company is subject to pricing pressures across its portfolio of branded and generic drugs, as well as reimbursement uncertainties that may impact revenue stability. Other risks include challenges related to commercial execution, manufacturing vulnerabilities, and competitive threats, exacerbated by a history of reputational concerns in the ACTH category that could affect market perception.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares